{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:06:56Z","timestamp":1782961616723,"version":"3.54.5"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Colorectal cancer (CRC) is a common malignancy with a relatively high incidence and mortality rate. Treatment options for metastatic CRC (mCRC) in the third-line setting remain limited. This article reports a case of colon cancer with liver metastases that progressed after comprehensive treatment but achieved a prolonged progression-free survival of over 38 months with third-line immunotherapy combined with targeted therapy. This aim is to improve understanding of CRC with liver metastasis and provide a clinical reference for managing similar cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 69-year-old male presented to the People\u2019s Hospital of Xiangxi Autonomous Prefecture in April 2021 with a 2-week history of fatigue and abdominal distension. His medical history included type 2 diabetes mellitus and diabetic peripheral neuropathy, managed with long-term insulin therapy. Based on clinical presentation, imaging studies, gastroscopy and colonoscopy, and pathological findings, he was diagnosed with moderately to poorly differentiated adenocarcinoma of the ascending colon with liver metastasis (cT4aN0M1a IVA, proficient mismatch repair [pMMR], clinical risk score [CRS] 2). The patient received 6 cycles of neoadjuvant chemotherapy with oxaliplatin, calcium folinate, and fluorouracil (the first 3 cycles combined with bevacizumab), followed by radical resection of the primary tumor and resection of complex liver metastases. Postoperatively, he underwent five cycles of adjuvant chemotherapy with oxaliplatin, calcium folinate, and fluorouracil (the last four cycles combined with bevacizumab). In November 2021, bilateral lung metastases were detected. The patient then received three cycles of chemotherapy with fluorouracil, calcium folinate, and irinotecan, but the disease continued to progress. From February 2022 to April 2025, third-line treatment with fruquintinib (targeted therapy) combined with sintilimab (immunotherapy) was initiated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Fruquintinib combined with sintilimab immunotherapy may represent a promising third-line treatment option for patients with pMMR mCRC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1639287","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:34:38Z","timestamp":1757655278000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term survival benefit from third-line treatment for advanced colon cancer: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Ju","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadong","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","article-title":"Colorectal cancer liver metastases - a population-based study on incidence, management and survival","volume":"18","author":"Engstrand","year":"2018","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-022-00922-2","article-title":"Colorectal liver metastasis: molecular mechanism and interventional therapy","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"B4","article-title":"Guidelines for the diagnosis and comprehensive treatment of liver metastasis from colorectal cancer in China (2023)","volume":"30","year":"2023","journal-title":"Chin Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"Jama"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.851756","article-title":"Fruquintinib in combination with PD-1 inhibitors in patients with refractory non-MSI-H\/pMMR metastatic colorectal cancer: A real-world study in China","volume":"12","author":"Gou","year":"2022","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2022.12.004","article-title":"Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases","volume":"181","author":"Guo","year":"2023","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01033","article-title":"Vitiligo adverse event observed in a patient with durable complete response after nivolumab for metastatic renal cell carcinoma","volume":"9","author":"Billon","year":"2019","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.04.019","article-title":"Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report","volume":"109","author":"Uenami","year":"2017","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1124730","article-title":"Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR\/MSS colorectal cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.984132","article-title":"Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report","volume":"13","author":"Mari","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1208418","article-title":"Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience","volume":"10","author":"Merli","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-081X(98)00008-X","article-title":"Drug-induced pemphigoid: bullous and cicatricial","volume":"16","author":"Vassileva","year":"1998","journal-title":"Clinics Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the canadian cancer trials group CO.26 Study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02728","article-title":"Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res:  Off J Am Assoc Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","article-title":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.3802\/jgo.2025.36.e45","article-title":"Functions, interactions and prognostic role of POLE: a bioinformatics analysis","volume":"36","author":"Carvajal-Veloza","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07769-3","article-title":"Prognostic genome and transcriptome signatures in colorectal cancers","volume":"633","author":"Nunes","year":"2024","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004487","article-title":"Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation","volume":"10","author":"Wen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02835-y","article-title":"Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer","volume":"42","author":"Kasi","year":"2023","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","article-title":"Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)","volume":"66","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00943-6","article-title":"Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","volume":"21","author":"Williams","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Sci (New York NY)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639287\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:34:40Z","timestamp":1757655280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639287\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1639287"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1639287","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"1639287"}}